FDA issues Complete Response Letter to Eli Lilly and Boehringer for empagliflozin to treat type 1 diabetes.
The FDA has issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for… read more.